Sofinnova Partners closes oversubscribed €82 million MD Start IV fund to build new MedTech startups
Sofinnova Partners, a Paris-based life sciences investor, has closed its Sofinnova MD Start IV fund at €82 million. The firm said the fund was oversubscribed and will build on a strategy dating back to 2008 that has created around a dozen companies. “Sofinnova MD Start is one of the few strategies in Europe focused on […] The post Sofinnova Partners closes oversubscribed €82 million MD Start IV…
Sofinnova Partners, a Paris-based life sciences investor, has successfully closed its Sofinnova MD Start IV fund at €82 million, exceeding its initial target. The fund, which was oversubscribed, will enable the company to continue its strategy of creating MedTech startups from the ground up. Sofinnova Partners, a European venture capital firm specializing in healthcare and sustainability, has backed over 500 companies and manages over €4 billion in assets across seven investment strategies.
The MD Start focus on MedTech company creation has yielded notable results, including acquisitions by Inari Medical and Abiomed, and successful Series A funding rounds.
Brief written by urgent.news from EU-Startups's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
